PDF(Pubmed)
Abstract：
BACKGROUND: The early detection of pancreatic cancer is an important step in reducing mortality by offering patients curative treatment. Screening strategies in risk populations and by means of different detection methods have been economically evaluated. However, a synthesis of screening studies to inform resource allocation towards early detection within the disease area has not been done. Therefore, studies evaluating the cost-effectiveness and costs of screening for pancreatic cancer should be systematically reviewed.
METHODS: A systematic review of economic evaluations reporting the cost-effectiveness or costs of pancreatic cancer screening will be conducted. The electronic databases Medline, Web of Science and EconLit will be searched without geographical or time restrictions. Two independent reviewers will select eligible studies based on predefined criteria. The study quality will be assessed using the Consolidated Health Economic Evaluation Reporting Standards statement and the Bias in Economic Evaluation checklist. One reviewer will extract relevant data and a second reviewer will cross-check compliance with the extraction sheet. Key items will include characteristics of screened individuals, the screening strategies used, and costs, health effects and cost-effectiveness as study outputs. Differences of opinion between the reviewers will be solved by consulting a third reviewer.
BACKGROUND: Ethics approval is not required for this study since no original data will be collected. The results will be disseminated through presentations at conferences and publication in a peer-reviewed journal. The results of the systematic review will inform future economic evaluations of pancreatic screening, which provide guidance for decision-making in healthcare resource prioritisation.
UNASSIGNED: CRD42023475348.
METHODS: A systematic review of economic evaluations reporting the cost-effectiveness or costs of pancreatic cancer screening will be conducted. The electronic databases Medline, Web of Science and EconLit will be searched without geographical or time restrictions. Two independent reviewers will select eligible studies based on predefined criteria. The study quality will be assessed using the Consolidated Health Economic Evaluation Reporting Standards statement and the Bias in Economic Evaluation checklist. One reviewer will extract relevant data and a second reviewer will cross-check compliance with the extraction sheet. Key items will include characteristics of screened individuals, the screening strategies used, and costs, health effects and cost-effectiveness as study outputs. Differences of opinion between the reviewers will be solved by consulting a third reviewer.
BACKGROUND: Ethics approval is not required for this study since no original data will be collected. The results will be disseminated through presentations at conferences and publication in a peer-reviewed journal. The results of the systematic review will inform future economic evaluations of pancreatic screening, which provide guidance for decision-making in healthcare resource prioritisation.
UNASSIGNED: CRD42023475348.
摘要：
背景：胰腺癌的早期发现是通过为患者提供治愈性治疗来降低死亡率的重要步骤。已对风险人群中的筛查策略以及通过不同的检测方法进行了经济评估。然而,尚未进行筛查研究的综合，以告知资源分配，以便在疾病区域内进行早期发现。因此,评估胰腺癌筛查成本效益和成本的研究应进行系统回顾.
方法：将对报告胰腺癌筛查的成本效益或成本的经济学评价进行系统评价。电子数据库Medline，WebofScience和EconLit将不受地理或时间限制进行搜索。两名独立审核员将根据预定义的标准选择符合条件的研究。将使用综合卫生经济评估报告标准声明和经济评估清单中的偏差来评估研究质量。一个审阅者将提取相关数据，第二个审阅者将交叉检查与提取表的合规性。关键项目将包括筛选个体的特征，使用的筛查策略，和成本，健康影响和成本效益作为研究产出。审稿人之间的意见分歧将通过咨询第三位审稿人来解决。
背景：本研究不需要伦理批准，因为不会收集原始数据。结果将通过在会议上的演讲和在同行评审的期刊上发表来传播。系统评价的结果将为未来胰腺筛查的经济评估提供信息，为医疗资源优先级的决策提供指导。
■CRD42023475348。
方法：将对报告胰腺癌筛查的成本效益或成本的经济学评价进行系统评价。电子数据库Medline，WebofScience和EconLit将不受地理或时间限制进行搜索。两名独立审核员将根据预定义的标准选择符合条件的研究。将使用综合卫生经济评估报告标准声明和经济评估清单中的偏差来评估研究质量。一个审阅者将提取相关数据，第二个审阅者将交叉检查与提取表的合规性。关键项目将包括筛选个体的特征，使用的筛查策略，和成本，健康影响和成本效益作为研究产出。审稿人之间的意见分歧将通过咨询第三位审稿人来解决。
背景：本研究不需要伦理批准，因为不会收集原始数据。结果将通过在会议上的演讲和在同行评审的期刊上发表来传播。系统评价的结果将为未来胰腺筛查的经济评估提供信息，为医疗资源优先级的决策提供指导。
■CRD42023475348。
